SEATTLE, April 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today presentation of preclinical data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The data presented demonstrated the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule, its differentiation from monospecific approaches, and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.
CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma
B-cell depletion with agents such as Rituxan(R) has proven successful in the treatment of hematological malignancies in the clinic, but patients still relapse and become refractory. Strategies to improve efficacy of B-cell directed therapies include boosting the cytotoxicity of agents and expanding to targets beyond CD20.
The objective of this preclinical model was to evaluate Trubion's SCORPION multispecific therapeutic as a next-generation candidate for oncology. An optimal bispecific molecule was identified that demonstrated highly potent activities against B-cell lymphoma cells in vitro.
The CD79BxDR SCORPION can bind to two different targets: CD79B, a lineage-restricted component of the B-cell antigen receptor, and HLA-DR, an HLA Class II molecule. Target binding by the SCORPION molecule has an affinity similar to Trubion's Small Modular Immunopharmaceutical (SMIP(TM)) proteins or monoclonal antibodies against the same target, but can bind both targets simultaneously. Results showed the CD79BxDR SCORPION molecule elicited strong Antibody-Dependent Cellular Cytotoxicity (ADCC) as well as highly potent direct killing, confirming the ability of Trubion's SCORPION molecules to retain key effector functions that are known to be related to efficacy of monoclonal antibodies. In addition, the data also demonstrated in assays against the NHL-derived DoHH2 cell line, that Trubion's SCORPION multispecific therapeutic was 100 times more potent than both rituximab and the combination of the individual mono-specific SMIP molecules against the respective CD79B and HLA-DR targets. This enhanced potency was shown to be restricted to the depletion of B-cells when in the presence of T cells, as 48 hour incubation with primary human peripheral blood mononuclear cells showed selective depletion of B (CD19+) but not T (CD3+) cells.
Trubion's SCORPION(TM) Therapeutics
Like Trubion's SMIP(TM) therapeutics -- single-chain polypeptides comprising one binding domain, one hinge domain and one effector domain -- SCORPION therapeutics are also novel, single-chain polypeptides comprised of functional domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion's SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor interactions or that manipulate cellular signaling pathways by cross-linking multiple cell surface receptors. SCORPION therapeutics have long in vivo half-lives, can have other intact effector functions if appropriate, and have manufacturing profiles consistent with clinical and commercial development.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary SMIP product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2a clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's future regulatory filings and the timing and outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the development of SCORPION multispecific therapeutics, the clinical advancement of TRU-016, the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the company's annual report on Form 10-K for the period ended December 31, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
Contact: Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. (206) 838-0500 firstname.lastname@example.org http://www.trubion.com Waggener Edstrom Worldwide Healthcare Amy Petty Senior Account Executive (617) 576-5788 email@example.com
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved